“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable ...

Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...

Sonelokimab, adalimumab, lutikizumab, and bimekizumab are the top-rated treatments for moderate-to-severe HS, a network ...

SAN DIEGO — An intravenous formulation of secukinumab met all primary efficacy endpoints, with an attractive safety profile, in patients with axial spondyloarthritis over 52 weeks, according to ...

Basel, November 15, 2014 - Novartis announced today results from the MEASURE 1 and MEASURE 2 pivotal Phase III studies of AIN457 (secukinumab) in ankylosing spondylitis (AS).In the studies ...

BOSTON — The human monoclonal antibody secukinumab (Novartis), which selectively neutralizes interleukin (IL)-17A, is safe and effective for patients with ankylosing spondylitis and psoriatic ...

Secukinumab, an anti-IL-17A monoclonal antibody biologic drug, showed promise as a treatment for patients with active ankylosing spondylitis, according to new research. Ankylosing spondylitis, or ...

Although secukinumab performs similarly to adalimumab in patients with spondyloarthritis who failed their first biological treatment, adalimumab proved superior in those who failed multiple ...

Overview of the clinical trials . 3.1 The company did a systematic review of the literature to identify studies evaluating the clinical effectiveness and safety of secukinumab for treating people with ...

Bimekizumab versus Secukinumab in Moderate-to-Severe Plaque Psoriasis – Dual interleukin-17A/17F inhibition clears skin better than interleukin-17A inhibition alone.

Overview of the clinical trials . 3.1 The company did a systematic review of the literature to identify studies evaluating the clinical effectiveness and safety of secukinumab for treating people with ...